Abstract:Osteosarcoma (OS) is an aggressive bone malignancy affecting children and young adults. Implementation and optimization of neoadjuvant chemotherapy led to significant improvements in outcome, but patients with recurrence or metastases at diagnosis continue to have poor prognosis. Whole genome sequencing (WGS) revealed that a hallmark of OS is a highly rearranged genome with complex copy number aberrations rather than point mutations. A better understanding of the key genomic and epigenetic factors driving clonal evolution may provide insights into the tumor progression and the therapy response. Canine OS recapitulates the majority of the hallmark genetic and molecular factors of human OS and is recognized as an informative model. A significant difference is that initial surgery in canine OS allows us to explore tumor evolution unperturbed by treatment, providing invaluable resources to study the genetic and molecular landscape of tumor evolution. Here, we present the first study to date in which we performed bulk WGS of multiple tumor sites and distal normal tissue in two dogs using nanopore long-read sequencing to analyze the genetic and epigenetic evolution of OS. In both subjects, somatic structural variation detection using Severus revealed chromothripsis-like rearrangements in chr11, leading to the deletion of Cdkn2a, a known cell cycle regulator and tumor suppressor. Interestingly, in one of the subjects, the majority of the SVs (n = 131) shared across all the samples were localized on chr5, coinciding with perturbed copy number profiles and bi-allelic frequency of the SNVs, with all mutations identified using complementary bioinformatics analysis of the same native nanopore reads. The multi-site sample analysis identified subclonal structural alterations in TP53 and ATRX genes. With phased nanopore reads, we observed subject-specific copy-neutral loss-of-heterozygosity events and long identical-by-descent blocks. Haplotype-specific copy-number analysis of tumors showed different aneuploidy patterns in both subjects, highlighted clonal compositions of samples from distinct sites, and identified regions of copy-number heterogeneity. Furthermore, phased nanopore reads also revealed haplotype-specific 5mC and 5hmC methylation differences across tumor samples, where samples from different sites of the same tumor demonstrate distinct methylation patterns that overlap DLG2, RUNX2, KDR, and other genes known as mutational hotspots in canine/human OS. Overall, we showcase how a single sequencing assay allows for a joint analysis of genetic and epigenetic tumor alterations, thus providing a richer understanding of the drivers of somatic evolution and their association with the molecular landscape in the canine OS. These findings can be translated into human disease and shed light on tumor progression and therapy response. Citation Format: Ayse Keskus, Sergey Aganezov, Tanveer Ahmad, Xiaoguang Dai, Robert Walker, John Beaulaurier, Scott Hickey, Sissel Juul, Amy Kathleen LeBlanc, Paul S. Meltzer, Mikhail Kolmogorov. Native nanopore sequencing of multiple tumor sites reveals genetic and epigenetic intra-tumor heterogeneity in canine osteosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5665.

Immunohistochemical Investigation into Protein Expression Patterns of FOXO4, IRF8 and LEF1 in Canine Osteosarcoma

Molecular Characterisation of Canine Osteosarcoma in High Risk Breeds

Transcriptomic Analysis of Canine Osteosarcoma from a Precision Medicine Perspective Reveals Limitations of Differential Gene Expression Studies

Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray

Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma

Special AT-rich sequence-binding protein 2 immunohistochemistry in the diagnosis of osteosarcoma in dogs

Investigating Cox-2 and EGFR as Biomarkers in Canine Oral Squamous Cell Carcinoma: Implications for Diagnosis and Therapy

Characterization of expression and prognostic implications of transforming growth factor beta, programmed death-ligand 1, and T regulatory cells in canine histiocytic sarcoma

Large Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes

Single-cell RNA sequencing reveals the cellular and molecular heterogeneity of treatment-naïve primary osteosarcoma in dogs

Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach

A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs

Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B

A Comparative Study on Radiosensitivity of Canine Osteosarcoma Cell Lines Subjected to Spatially Fractionated Radiotherapy

MicroRNAs as Biomarkers in Canine Osteosarcoma: A New Future?

Abstract 5665: Native nanopore sequencing of multiple tumor sites reveals genetic and epigenetic intra-tumor heterogeneity in canine osteosarcoma

Identification of Tumorigenicity-Associated Genes in Osteosarcoma Cell Lines Based on Bioinformatic Analysis and Experimental Validation.

SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma

Prevalence of 5-lipoxygenase expression in canine osteosarcoma and the effects of a dual 5-lipoxygenase/cyclooxygenase inhibitor on osteosarcoma cells in vitro and in vivo

Cross-Species Gene Expression Analysis Reveals Gene Modules Implicated in Human Osteosarcoma.

Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors